AL
FPRX

Airain Ltd’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Airain Ltd’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$500K Sell
16,594
-3,926
-19% -$123K 0.02% 541
2017
Q1 		$742K Buy
+20,520
New +$904K 0.04% 409
2015
Q2 		– Sell
-17,552
Closed -$401K – 1163
2015
Q1 		$401K Buy
+17,552
New +$443K 0.02% 559
2014
Q3 		– Sell
-11,588
Closed -$180K – 1041
2014
Q2 		$180K Buy
+11,588
New +$166K 0.01% 677

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Airain Ltd's FPRX Position: Q2 2017 in Review

Airain Ltd reduced its Five Prime Therapeutics, Inc. (FPRX) stake by 19% in Q2 2017, selling an estimated $123K and leaving 16,594 shares worth $500K. The position accounts for 0.02% of the portfolio, ranked #541.

Airain Ltd first reported a position in FPRX in Q2 2014 and has held it in 4 quarters since. The position peaked at $742K in Q1 2017. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Airain Ltd held 16,594 shares of Five Prime Therapeutics, Inc. worth $500K as of Q2 2017.
  • Airain Ltd sold 3,926 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $123K.
  • Five Prime Therapeutics, Inc. made up 0.02% of Airain Ltd's portfolio in Q2 2017, its #541 holding.
  • Airain Ltd first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and has held it in 4 quarters since.
  • Airain Ltd's Five Prime Therapeutics, Inc. position peaked at $742K in Q1 2017.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.